NCI backs development of lung cancer test

08/27/2013 | GenomeWeb Daily News (free registration)

Insight Genetics will use a $1.5 million grant from the National Cancer Institute to further develop its non-small cell lung cancer diagnostic test. Specifically, Insight said it will develop a panel of tests for detecting and characterizing oncogenic DEPDC1, RET and ROS1 in NSCLC patients who have tested triple negative for KRAS, EGFR or ALK gene mutations.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY